Boryung Biopharma Co., Ltd.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
- Conditions
- Hep AHepatitis A
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Boryung Biopharma Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT05613127
- Locations
- 🇰🇷
The Catholic University of Korea, ST. Vincent's Hospital, Suwon, Korea, Republic of
🇹🇭Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
- Conditions
- DiphtheriaTetanus
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Boryung Biopharma Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT04618939
- Locations
- 🇰🇷
Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷The Catholic University of Korea Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of
🇰🇷The Catholic University of Korea Incheon St. Mary's Hospital, Incheon, Korea, Republic of
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
- Conditions
- DiphtheriaPoliomyelitisTetanusPertussis
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Boryung Biopharma Co., Ltd.
- Target Recruit Count
- 249
- Registration Number
- NCT04618640
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Hallym University Medical Center, Gyeonggi-do, Korea, Republic of
🇰🇷Changwon Fatima Hospital, Changwon, Korea, Republic of